

REFERENCES

1. Szekely CA, Breitner JCS, Zandi PP. *Prevention of Alzheimer's disease*. Int. Rev. Psychiatry. 2007;19:693-706.
2. Ghochikyan A. *Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy*. C.N.S. Neurol. Disord. Drug Targets. 2009;8:128.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. *Forecasting the global burden of Alzheimer's disease*. Alzheimers Dement. 2007;3:186-191.
4. Brasnjevic I, Steinbusch HWM, Schmitz C, Martinez-Martinez P. *Delivery of peptide and protein drugs over the blood-brain barrier*. Prog. Neurobiol. 2009;87:212-251.
5. Ingkaninan K, Changwijit K, Suwanborirux K. *Vobasinyl-iboga bisindole alkaloids, potent acetylcholinesterase inhibitors from Tabernaemontana divaricata root*. J. Pharm. Pharmacol. 2006;58:847-852.
6. Martin R, Farlow JLC. *Effective Pharmacologic Management of Alzheimer's Disease*. Am. J. Med. 2007;120:388-397.
7. Mukherjee PK, Kumar V, Mal M, Houghton PJ. *Acetylcholinesterase inhibitors from plants*. Phytomedicine. 2007;14:289-300.

8. Ingkaninan K, Temkitthawon P, Chuenchom K, Yuyaem T, Thongnoi W. *Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies*. J. Ethnopharmacol. 2003;89:261-264.
9. Chattipakorn S, Pongpanparadorn A, Pratchayasakul W, Pongchaidacha A, Ingkaninan K, Chattipakorn N. *Tabernaemontana divaricata* extract inhibits neuronal acetylcholinesterase activity in rats. J. Ethnopharmacol. 2007;110:61-68.
10. Nakdook W, Khongsombat O, Taepavarapruk P, Taepavarapruk N, Ingkaninan K. *The effects of Tabernaemontana divaricata* root extract on amyloid [beta]-peptide 25-35 peptides induced cognitive deficits in mice. J. Ethnopharmacol. 2010;130:122-126.
11. Lefevre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, Ho YY, Appel-Dingemanse S. *Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects*. J. Clin. Pharmacol. 2008;48:246-252.
12. Johnson N, Davis T, Bosanquet N. *The epidemic of Alzheimer's disease: how can we manage the costs?*. Pharmacoeconomics. 2000;18:215-223.
13. Wentrup A, Oertel WH, Dodel R. *Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease*. Drug. Des. Devel. Ther. 2008;2:245-254.

14. Winblad BB, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagal J, Lane R. *A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule*. Int. J. Geriatr. Psychiatry. 2007;22:456-467.
15. El Maghraby GM. *Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: Effects of cosurfactants*. Int. J. Pharm. 2008;355:285-292.
16. Schwuger MJ, Stickdorn K, Schomaecker R. *Microemulsions in technical processes*. Chem. Rev. 1995;95:849-864
17. Lane RM, Potkin SG, Enz A. *Targeting acetylcholinesterase and butyrylcholinesterase in dementia*. Int. J. Neuropsychopharmacol. 2005;9:101-124.
18. Richter JA, Perry EK, Tomlinson BE. 1980. *Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer's disease*. Life Sci. 1980;26:1683-1689.
19. Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry TA, Lee B, Ingram DK, Lahiri DK. *A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase*. Curr. Med. Res. Opin. 2001;17:159-165.
20. Sommer B. *Alzheimer's disease and the amyloid cascade hypothesis: ten years on*. Curr. Opin. Pharmacol. 2002;2:87-92.
21. Vassar R. *[beta]-Secretase (BACE) as a drug target for alzheimer's disease*. Adv. Drug Deliv. Rev. 2002;54:1589-1602.

22. Kokjohn TA, Roher AE. *Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations and contributions.* *Alzheimers Dement.* 2009;5:340-347.
23. Patterson C, Feightner JW, Garcia A, Hsiung GYR, MacKnight C, Sadovnick AD. *Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease.* *Can. Med. Assoc. J.* 2008;178:548-556.
24. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JAT, Norton MC, Welsh-Bohmer KA, Breitner JC. *Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study.* *Arch. Neurol.* 2004;61:82-88.
25. Das A, Shanker G, Nath C, Pal R, Singh S, Singh HK. *A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba: Anticholinesterase and cognitive enhancing activities.* *Pharmacol. Biochem. Behav.* 2002;73:893-900.
26. Ortega MG, Agnese AM, Cabrera JL. *Anticholinesterase activity in an alkaloid extract of Huperzia saururus.* *Phytomedicine.* 2004;11:539-543.
27. Orhan I. *Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants.* *J. Ethnopharmacol.* 2004;91:57-60.
28. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. *Meta-analysis of six-month memantine trials in Alzheimer's disease.* *Alzheimers Dement.* 2007;3:7-17.

29. Pratchayasakul W, Pongchaidecha A, Chattipakorn N, Chattipakorn S. *Ethnobotany & ethnopharmacology of Tabernaemontana divaricata*. Indian J. Med. Res. 2008;127:317-335.
30. Van Beek TA, Verpoorte R, Svendsen AB, Leeuwenberg AJM, Bisset NG. *Tabernaemontana L. (Apocynaceae): A review of its taxonomy, phytochemistry, ethnobotany and pharmacology*. J. Ethnopharmacol. 1984;10:1-156.
31. Henriques AT, Melo AA, Moreno PRH, Ene LL, Henriques JAP, Schapoval EES. *Ervatamia coronaria: chemical constituents and some pharmacological activities*. J. Ethnopharmacol. 1996;50:19-25.
32. Naik A, Kalia YN, Guy RH. *Transdermal drug delivery: overcoming the skin's barrier function*. Pharm. Sci. Technol. To. 2000;3:318-326.
33. Kreilgaard M, Pedersen EJ, Jaroszewski JW. *NMR characterisation and transdermal drug delivery potential of microemulsion systems*. J. Control. Release. 2000;69:421-433.
34. Brasnjevic I, Steinbusch HWM, Schmitz C, Martinez-Martinez P. *Delivery of peptide and protein drugs over the blood-brain barrier*. Prog. Neurobiol. 2009;87:212-251.
35. Kogan A, Garti N. *Microemulsions as transdermal drug delivery vehicles*. Adv. Colloid Interface Sci. 2006;123-126:369-385.
36. Kindersley D. Skin. 2007 [updated 2007; cited 24th August 2010]; Available from: <http://www.factmonster.com/dk/science/encyclopedia/skin.html>.
37. Kalia YN, Guy RH. *Modeling transdermal drug release*. Adv. Drug Deliv. Rev. 2001;48:159-172.

38. Priano L, Gasco MR, Mauro A. *Transdermal treatment options for neurological disorders: impact on the elderly*. Drugs Aging. 2006;23:357-375.
39. Muhlack S, Przuntek H, Müller T. *Transdermal Rivastigmine Treatment Does Not Worsen Impaired Performance of Complex Motions in Patients with Alzheimer's Disease*. Pharmacopsychiatry. 2006;39:16-19.
40. Kankkunen T, Sulkava R, Vuorio M, Kontturi K, Hirvonen J. *Transdermal iontophoresis of tacrine in vivo*. Pharm. Res. 2002;19:705-708.
41. Krauel K, Girvan L, Hook S, Rades T. *Characterisation of colloidal drug delivery systems from the naked eye to Cryo-FESEM*. Micron. 2007;38:796-803.
42. Boonme P, Krauel K, Graf A, Rades T, Junyaprasert VB. *Characterization of Microemulsion Structures in the Pseudoternary Phase Diagram of Isopropyl Palmitate/Water/Brij 97:1-Butanol*. AAPS PharmSciTech. 2006;7:99-104.
43. Kreilgaard M. *Influence of microemulsions on cutaneous drug delivery*. Adv. Drug Deliv. Rev. 2002;54(Supplement 1):S77-S98.
44. Schmidts T, Nocker P, Lavi G, Kuhlmann J, Czermak P, Runkel F. *Development of an alternative, time and cost saving method of creating pseudoternary diagrams using the example of a microemulsion*. Colloids Surf. A. Physicochem. Eng. Asp. 2009;340:187-192.
45. Chaiana W, Saeio K, Hennink WE, Okonogi S. *Characterization of potent anticholinesterase plant oil based microemulsion*. Int. J. Pharm. 2010;401:32-40.

46. Sintov AC, Botner S. *Transdermal drug delivery using microemulsion and aqueous systems: influence of skin storage conditions on the in vitro permeability of diclofenac from aqueous vehicle systems*. Int. J. Pharm. 2006;311:55-62.
47. Sintov AC, Shapiro L. *New microemulsion vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo*. J. Control. Release. 2004;95:173-183.
48. Gupta RR, Jain SK, Varshney M. *AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil*. Colloids Surf. B. Biointerfaces. 2005;41:25-32.
49. Gallarate M, Carlotti ME, Trotta M, Bovo S. *On the stability of ascorbic acid in emulsified systems for topical and cosmetic use*. Int. J. Pharm. 1999;188:233-241.
50. Gasco MR, Trotta M. *Nanoparticles from microemulsions*. Int. J. Pharm. 1986;29:267-268.
51. Watnasirichaikul S, Davies NM, Rades T, Tucker IG. *Preparation of biodegradable insulin nanocapsules from biocompatible microemulsions*. Pharm. Res. 2000;17:684-689.
52. Chen H, Chang X, Du D, Li J, Xu H, Yang X. *Microemulsion-based hydrogel formulation of ibuprofen for topical delivery*. Int. J. Pharm. 2006;315:52-58.
53. Nesbitt M, McBurney RPH, Broin M, Beentje HJ. *Linking biodiversity, food and nutrition: The importance of plant identification and nomenclature*. J. Food Compost. Anal. 2009;23:486-498.

54. Xie Y, Jiang ZH, Zhou H, Cai X, Wong YF, Liu ZQ, Bian ZX, Xu HX, Liu L. *Combinative method using HPLC quantitative and qualitative analyses for quality consistency assessment of a herbal medicinal preparation.* J. Pharmaceut. Biomed. Anal. 2007;43:204-212.
55. Chou G, Xu SJ, Liu D, Koh GY, Zhang J, Liu Z. *Quantitative and fingerprint analyses of Chinese sweet tea plant (Rubus suavissimus S. Lee).* J. Agric. Food Chem. 2009;57:1076-1083.
56. Rhee IK, van de Meent M, Ingkaninan K, Verpoorte R. *Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining.* J. Chrom. A. 2001;915:217-223.
57. Ellman GL, Courtney KD. *A new and rapid colorimetric determination of acetylcholinesterase activity.* Biochem. Pharmacol. 1961;7:88-90.
58. Morris RGM. *Development of a water-maze procedure for studying spatial learning in the rat.* J. Neurosci. Methods. 1984;11:47-60.
59. Egashira N, Yuzurihara M, Hattori N, Sakakibara I, Ishige A. *Ninjin-yoei-to (Ren-Shen-Yang-Rong-Tang) and polygalae radix improves scopolamine-induced impairment of passive avoidance response in mice.* Phytomedicine. 2003;10:467-473.
60. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S. *SB-399885 is a potent, selective 5-HT₆ receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.* Eur. J. Pharmacol. 2006;553:109-119.

61. Dutta AK. *Physicochemical characterization of NPC 1161C, an 8-aminoquinoline anti-malarial drug, and its inclusion complexes with cyclodextrins in solution state*: THE UNIVERSITY OF MISSISSIPPI, 2006.
62. Khornkarn R, Okonogi S, Ampasavate C, Anuchapreeda S. *Investigation of fruit peel extracts as sources for compounds with antioxidant and antiproliferative activities against human cell lines*. Food Chem. Toxicol. 2010;48:2122-2129.
63. Ferderber K, Hook S, Rades T. *Phosphatidyl choline-based colloidal systems for dermal and transdermal drug delivery*. J. Liposome Res. 2009;19:267-277.
64. Taesotikul T, Panthong A, Kanjanapothi D, Verpoorte R, Scheffer J. *Hippocratic screening of ethanolic extracts from two Tabernaemontana species*. J. Ethnopharmacol. 1989;27:99-106.
65. Gong F, Liang YZ, Xie PS, Chau FT. *Information theory applied to chromatographic fingerprint of herbal medicine for quality control*. J. Chrom. A. 2003;1002:25-40.
66. Liang YZ, Xie P, Chan K. *Quality control of herbal medicines*. J. Chrom. B. 2004;812:53-70.
67. Leonard S, Capote R, Germonprez N, Van Puyvelde L, De Kimpe N, Vermeersch H, Rosier J, Maes L, Roets E, Hoogmartens J. *Liquid chromatographic method for analysis of saponins in Maesa balansae extract active against leishmaniasis*. J. Chroma. A. 2003;1012:39-46.
68. Theodoridis G, Papadoyannis I, Hermans-Lokkerbol A, Verpoorte R. *A study of the behaviour of some new column materials in the chromatographic analysis of Cinchona alkaloids*. Chromatographia. 1995;41:153-160.

69. Dhooghe L, Mesia K, Kohtala E, Tona L, Pieters L, Vlietinck AJ, Apers S. *Development and validation of an HPLC-method for the determination of alkaloids in the stem bark extract of Nauclea pobeguinii*. Talanta. 2008;76:462-468.
70. Neddermeyerand P, Rogers LB. *Gel filtration behavior of inorganic salts*. Anal. Chem. 1968;40:755-762.
71. Braga RM, Leitão Filho HF, De AM Reist F. ¹³C NMR analysis of alkaloids from *Peschiera fuchsiaefolia*. Phytochemistry. 1984;23:175-178.
72. Kam TS, Sim KM. *Five new iboga alkaloids from Tabernaemontana corymbosa*. J. Nat. Prod. 2002;65:669-672.
73. Kam TS, Sim KM, Pang HS. *New bisindole alkaloids from Tabernaemontana corymbosa*. J. Nat. Prod. 2003;66:11-16.
74. Kam TS, Pang HS, Choo YM, Komiyama K. *Biologically active ibogan and vallesamine derivatives from Tabernaemontana divaricata*. Chem. Biodivers. 2004;1:646-656.
75. Van Beek T, Verpoorte R, Svendsen AB, Fokkens R. *Antimicrobially active alkaloids from Tabernaemontana chippii*. J. Nat. Prod. 1985;48:400-423.
76. Perera P, Sandberg F, Van Beek T, Verpoorte R. *Alkaloids of stem and rootbark of Tabernaemontana dichotoma*. Phytochemistry. 1985;24:2097-2104.
77. Zhao Q, Tang XC. *Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine*. Eur. J. Pharmacol. 2002;455:101-107.

78. I.C.H. Guideline. *Validation of analytical procedures: text and methodology Q2 (R1)*. IFPMA: Geneva (2005).
79. Farfara D, Lifshitz V, Frenkel D, *Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease*. J. Cell. Mol. Med. 2008;12:762-780.
80. Perry E, Perry R, Blessed G, Tomlinson B. *Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia*. Neurobiological. 1978;4:273-277.
81. Snyder SE, Gunupudi N, Sherman PS, Butch ER, Skaddan MB, Kilbourn MR, Koeppe RA, Kuhl DE. *Radiolabeled cholinesterase substrates [colon] in vitro methods for determining structure–activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity*. J. Cereb. Blood Flow Metab. 2001;21:132-143.
82. Mukherjee PK, Kumar V, Mal M, Houghton PJ. *Acetylcholinesterase inhibitors from plants*. Phytomedicine. 2007;14:289-300.
83. Howes MJR, Houghton PJ. *Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function*. Pharmacol. Biochem. Behav. 2003;75:513-527.
84. Scarpini E, Schelterns P, Feldman H. *Treatment of Alzheimer's disease; current status and new perspectives*. Lancet Neurol. 2003;2:539-547.

85. Greig NH, Utsuki T, Wang Y, Ingram DK, Mamczar J, Rogers J, Yun QS, Holloway HW, Perry TA, Sambamurti K, Scali C, Pepeu G, Lahiri DK. *P1-414 selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers amyloid-beta peptide in rodents: a new treatment strategy for Alzheimer's disease*. Neurobiol. Aging. 2004;25:S216-S1216.
86. Van Beek AHEA, Claassen JAHR. *The cerebrovascular role of the cholinergic neural system in Alzheimer's disease*. Behav. Brain Res. 2011;221:537-542.
87. Lefevre G, Pommier F, Sedek G, Allison M, Huang HL, Kiese B, Ho YY, Appel-Dingemanse S. *Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects*. J. Clin. Pharmacol. 2008;48:246-252.
88. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. *Rivastigmine exposure provided by a transdermal patch versus capsules*. Curr. Med. Res. Opin. 2007;23:3199-3204.
89. Klinkenbergand I, Blokland A. *The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies*. Neurosci. Biobehav. Rev. 2010;34:1307-1350.
90. Maurice T, Lockhart BP, Privat A. *Amnesia induced in mice by centrally administered [beta]-amyloid peptides involves cholinergic dysfunction*. Brain Res. 1996;706:181-193.
91. Saraf M, Prabhakar S, Anand A. *Bacopa monniera alleviates N_ω-nitro-L-arginine-induced but not MK-801-induced amnesia: A mouse Morris water maze study*. Neuroscience. 2009;160:149-155.

92. Meylanand WM, Howard PH. *Atom/fragment contribution method for estimating octanol–water partition coefficients*. J. Pharm. Sci. 1995;84:83-92.
93. Hawkinsand GS, Reifenrath WG. *Influence of skin source, penetration cell fluid, and, partition coefficient on in vitro skin penetration*. J. Pharm. Sci. 1986;75:378-381.
94. Cruciani G, Crivori P, Carrupt PA, Testa B. *Molecular fields in quantitative structure-permeation relationships: the VolSurf approach*. J. Mol. Struct-THEOCHEM. 2000;503:17-30.
95. Ahmed A, Karki N, Charde R, Charde M, Gandhare B. *Transdermal drug delivery systems: an overview*. Int. J. Biomed. Adv. Res. 2010;2:38-56.
96. Kibbey CE, Poole SK, Robinson B, Jackson JD, Durham D. *An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment*. J. Pharm. Sci. 2001;90:1164-1175.
97. Lewis DF, Ioannides C, Parke DV. *COMPACT and molecular structure in toxicity assessment: a prospective evaluation of 30 chemicals currently being tested for rodent carcinogenicity by the NCI/NTP*. Environ. Health Perspect. 1996;104:1011-1016.
98. Mutlu NB, Degim Z, Yilmaz S, Essiz D, Nacar A. *New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations*. Drug Dev. Ind. Pharm. 2011;37:1-15.

99. Wilkinson SC, Maas WJM, Nielsen JB, Greaves LC, van de Sandt JJM, Williams FM. *Interactions of skin thickness and physicochemical properties of test compounds in percutaneous penetration studies*. Int. Arch. Occup. Environ. Health. 2006;79:405-413.
100. Provencher-Mandeville J, Descôteaux C, Mandal SK, Leblanc V, Asselin É, Bérubé G. *Synthesis of 17 [beta]-estradiol-platinum (II) hybrid molecules showing cytotoxic activity on breast cancer cell lines*. Bioorg. Med. Chem. Lett. 2008;18:2282-2287.
101. Raevsky OA. *Molecular lipophilicity calculations of chemically heterogeneous chemicals and drugs on the basis of structural similarity and physicochemical parameters*. SAR QSAR Environ. Res. 2001;12:367-381.
102. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. *Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines*. Cancer Res. 1988;48:4827-4833.
103. Williams AC, Barry BW. *Penetration enhancers*. Adv. Drug Deliv. Rev. 2004;56:603-618.
104. Asbill CS, Michniak BB. *Percutaneous penetration enhancers: local versus transdermal activity*. Pharm. Sci. Technol. To. 2000;3:36-41.
105. Sinhaand V, Kaur MP. *Permeation enhancers for transdermal drug delivery*. Drug Dev. Ind. Pharm. 2000;26:1131-1140.
106. Sagitani H, Friberg S. *Microemulsion systems with a non-ionic cosurfactant*. J. Disper. Sci. Technol. 1980;1:1151-1164.

107. Ben-Moshe M, Magdassi S. *Surface activity and micellar properties of anionic gemini surfactants and their analogues*. Colloids Surf. A: Physicochem. Eng. Aspects 2004;250:403-408.
108. Baker RC, Florence AT, Ottewill RH, Tadros TF. *Investigations into the formation and characterization of microemulsions. II. Light scattering conductivity and viscosity studies of microemulsions*. J. Colloid Interface Sci. 1984;100:332-349.
109. Babak VG, Stébé MJ. *Highly concentrated emulsions: physicochemical principles of formulation*. J. Disper. Sci. Technol. 2002;23:1-22.
110. Li X, Kunieda H. *Catanionic surfactants: microemulsion formation and solubilization*. Curr. Opin. Colloid Interface Sci. 2003;8:327-336.
111. Martin AN. *Physical pharmacy*. Am. J. Med. Sci. 1961;241:138-140.
112. Drew M. *Solubilization, micellar catalysis, and microemulsions*. In: Surfaces, Interfaces, and Colloids. second ed, 2002; pp.397-414.
113. Lawrence MJ, Rees GD. *Microemulsion-based media as novel drug delivery systems*. Adv. Drug Deliv. Rev. 2000;45:89-121.
114. Tenjarla S. *Microemulsions: an overview and pharmaceutical applications*. Crit. Rev. Ther. Drug Carrier Syst. 1999;16:461-521.
115. Liu D, Ma J, Cheng H, Zhao Z. *Solubilization behavior of mixed reverse micelles: effect of surfactant component, electrolyte concentration and solvent*. Colloids Surf. A: Physicochem. Eng. Aspects 1998;143:59-68.
116. Yuan Y, Li S, Mo F, Zhong D. *Investigation of microemulsion system for transdermal delivery of meloxicam*. Int. J. Pharm. 2006;321:117-123.

117. Carlfors J, Blute I, Schmidt V. *Lidocaine in microemulsion dermal delivery system*. J. Disper. Sci. Technol. 1991;12:467-482.
118. Mo C, Zhong M, Zhong Q. *Investigation of structure and structural transition in microemulsion systems of sodium dodecyl sulfonate + nheptane + n-butanol +water by cyclic voltammetric and electrical conductivity measurements*. J. Electroanal. Chem. 2000;493:100-107.
119. Kumar P, Mittal KL. *Handbook of Microemulsion Science and Technology*. Marcel Dekker, Inc., New York, 1999; pp.755-756.
120. Bauduin P, Touraud D, Kunz W, Savelli MP, Pulvin S, Ninham BW. *The influence of structure and composition of a reverse SDS microemulsion on enzymatic activities and electrical conductivities*. J. Colloid Interface Sci. 2005;292:244-254.
121. Alany RG, Rades T, Agatonovic-Kustrin S, Davies NM, Tucker IG. *Effects of alcohols and diols on the phase behaviour of quaternary systems*. Int. J. Pharm. 2000;196:141-145.
122. Huibers PDT, Lobanov VS, Katritzky AR, Shah DO, Karelson M. *Prediction of Critical Micelle Concentration Using a Quantitative Structure- Property Relationship Approach*. Langmuir. 1996;12:1462-1470.
123. Hait SK, Moulik SP. *Determination of critical micelle concentration (CMC) of nonionic surfactants by donor-acceptor interaction with iodine and correlation of CMC with hydrophile-lipophile balance and other parameters of the surfactants*. J. Surfactants Deterg. 2001;4:303-309.

124. Palazzo G, Lopez F, Giustini M, Colafemmina G, Ceglie A. *Role of the Cosurfactant in the CTAB/Water/n-Pentanol/n-Hexane Water-in-Oil Microemulsion. 1. Pentanol Effect on the Microstructure.* J. Phys. Chem. B. 2003;107:1924-1931.
125. Zhang X, Zhuang W, Cui X, He H, Huang X. *Preparation of BaMgAl (10) O (17): Eu (2+) and its phase behavior in microemulsion system.* J. Rare Earths (Engl. Ed.). 2006;24:736-739.
126. Liu L, Tian S, Ning P. *Phase behavior of TXs/toluene/water microemulsion systems for solubilization absorption of toluene.* J. Environ. Sci. 2010;22:271-276.
127. Salabat A, Alinoori M. *Salt effect on aqueous two-phase system composed of nonylphenyl ethoxylate non-ionic surfactant.* Calphad. 2008;32:611-614.
128. García SF, Eliosa JG, Salas PA, Hernández-Garduza O, Ápam- Martínez D. *Modeling of microemulsion phase diagrams from excess Gibbs energy models.* Chem. Eng. J. 2001;84:257-274.
129. Dixit SG, Mahadeshwar AR, Haram SK. *Some aspects of the role of surfactants in the formation of nanoparticles.* Colloids Surf. A. 1998;133:69-75.
130. Vaddi H, Ho P, Chan S. *Terpenes in propylene glycol as skin penetration enhancers: Permeation and partition of haloperidol, fourier transform infrared spectroscopy, and differential scanning calorimetry.* J. Pharm. Sci. 2002;91:1639-1651.

131. Kale NJ, Allen LV. *Studies on microemulsions using Brij 96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants*. Int. J. Pharm. 1989;57:87-93.
132. Graf A, Ablinger E, Peters S, Zimmer A, Hook S, Rades T. *Microemulsions containing lecithin and sugar-based surfactants: Nanoparticle templates for delivery of proteins and peptides*. Int. J. Pharm. 2008;350:351-360.
133. Senatra D, Gambi CMC, Carlà M, Chittofrati A. *Thermal behaviour of perfluoropolyether W/O percolative microemulsions*. J. Therm. Anal. Calorim. 1999;56:1335-1346.
134. Junyaprasert V, Boonme P, Songkro S, Krauel K, Rades T. *Transdermal delivery of hydrophobic and hydrophilic local anesthetics from o/w and w/o Brij 97-based microemulsions*. J. Pharm. Pharmaceut. Sci. 2007;10:288-298.
135. Garti N, Aserin A, Tiunova I, Fanun M. *A DSC study of water behavior in water-in-oil microemulsions stabilized by sucrose esters and butanol*. Colloids Surf. A. Physicochem. Eng. Asp. 2000;170:1-18.
136. Lim GK, Wang J, Ng SC, Chew CH, Gan LM. *Processing of hydroxyapatite via microemulsion and emulsion routes*. Biomaterials. 1997;18:1433-1439.
137. Sripriya R, Muthu Raja K, Santhosh G, Chandrasekaran M, Noel M. *The effect of structure of oil phase, surfactant and co-surfactant on the physicochemical and electrochemical properties of bicontinuous microemulsion*. J. Colloid Interface Sci. 2007;314:712-717.

138. Georges J, Chen J. *Microemulsions studies: correlation between viscosity, electrical conductivity and electrochemical and fluorescent probe measurements*. Colloid Polym. Sci. 1986;264:896-902.
139. Beneteau C, Khavinson D. *The isoperimetric inequality via approximation theory and free boundary problems*. Comput. Meth. Funct. Theor. 2006;6:253-274.
140. Yaghmur A, Aserin A, Antalek B, Garti N. *Microstructure considerations of new five-component Winsor IV food-grade microemulsions studied by pulsed gradient spin-echo NMR, conductivity, and viscosity*. Langmuir. 2003;19:1063-1068.
141. Paul BK, Moulik SP. *Microemulsions: an overview*. J. Disper. Sci. Technol. 1997;18:301-367.
142. Burghardt WR, Krishnan K, Bates FS, Lodge TP. *Linear viscoelasticity of a polymeric bicontinuous microemulsion*. Macromolecules. 2002;35:4210-4215.
143. Megrab NA, Williams AC, Barry BW. *Oestradiol permeation across human skin, silastic and snake skin membranes: the effects of ethanol/water co-solvent systems*. Int. J. Pharm. 1995;116:101-112.
144. Morimoto H, Wada Y, Seki T, Sugibayashi K. *In vitro skin permeation of morphine hydrochloride during the finite application of penetration-enhancing system containing water, ethanol and L-menthol*. Biol. Pharm. Bull. 2002;25:134-136.
145. Schwarz JS, Weisspapir MR, Friedman DI. *Enhanced transdermal delivery of diazepam by submicron emulsion (SME) creams*. Pharm. Res. 1995;12:687-692.

146. Paolino D, Ventura CA, Nistico S, Puglisi G, Fresta M. *Lecithin microemulsions for the topical administration of ketoprofen: percutaneous adsorption through human skin and in vivo human skin tolerability*. Int. J. Pharm. 2002;244:21-31.
147. Kim S, Ng WK, Shen S, Dong Y, Tan RBH. *Phase behavior, microstructure transition, and antiradical activity of sucrose laurate/propylene glycol/the essential oil of Melaleuca alternifolia/water microemulsions*. Colloids Surf. A. 2009;348:289-297.
148. Alany RG, Tucker IG, Davies NM, Rades T. *Characterizing colloidal structures of pseudoternary phase diagrams formed by oil/water/amphiphile systems*. Drug Dev. Ind. Pharm. 2001;27:31-38.
149. Kogan A, Shalev DE, Raviv U, Aserin A, Garti N. *Formation and characterization of ordered bicontinuous microemulsions*. J. Phys. Chem. B. 2009;113:10669-10678.
150. Liu H, Wang Y, Lang Y, Yao H, Dong Y, Li S. *Bicontinuous Cyclosporin a loaded Water-AOT/Tween 85-isopropylmyristate microemulsion: Structural characterization and dermal pharmacokinetics in vivo*. J. Pharm. Sci. 2009;98:1167-1176.
151. Podlogar F, Gaperlin M, Tomi M, Jamnik A, Roga M. *Structural characterisation of water-Tween 40o/Imwitor 308o-isopropyl myristate microemulsions using different experimental methods*. Int. J. Pharm. 2004;276:115-128.

152. Zhang J, Michniak-Kohn B. *Investigation of microemulsion microstructures and their relationship to transdermal permeation of model drugs: Ketoprofen, lidocaine, and caffeine*. Int. J. Pharm. 2011;421:34-44.
153. Zapf A, Beck R, Platz G, Hoffmann H. *Calcium surfactants: a review*. Adv. Colloid Interface Sci. 2003;100:349-380.
154. Nakamura N., Tagawa T., Kihara K., Tobita I., Kunieda H. *Phase transition between microemulsion and lamellar liquid crystal*. Langmuir. 1997;13:2001-2006.
155. Walker RB, Smith EW. *The role of percutaneous penetration enhancers*. Adv. Drug Deliv. Rev. 1996;18:295-301.
156. Sheth NV, Freeman DJ, Higuchi WI, Spruance SL. *The influence of Azone, propylene glycol and polyethylene glycol on in vitro skin penetration of trifluorothymidine*. Int. J. Pharm. 1986;28:201-209.
157. Barry B. *Mode of action of penetration enhancers in human skin*. J. Controlled Release. 1987;6:85-97.
158. El Maghraby GM. *Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: Effect of phase transition*. Colloids Surf. B Biointerfaces. 2010;75:595-600.
159. Savić SD, Savić MM, Vesić SA, Vuleta GM, Müller-Goymann CC. *Vehicles based on a sugar surfactant: Colloidal structure and its impact on in vitro/in vivo hydrocortisone permeation*. Int. J. Pharm. 2006;320:86-95.

160. Cornwell PA, Barry BW, Bouwstra JA, Gooris GS. *Modes of action of terpene penetration enhancers in human skin; differential scanning calorimetry, small-angle X-ray diffraction and enhancer uptake studies*. Int. J. Pharm. 1996;127:9-26.
161. Asbill CS, Michniak BB. *Percutaneous penetration enhancers: local versus transdermal activity*. Pharm. Sci. Technol. To. 2000;3:36-41.
162. Williams AC, Barry BW. *Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement*. Pharm. Res. 1991;8:17-24.
163. Williams AC, Barry BW. *The enhancement index concept applied to terpene penetration enhancers for human skin and model lipophilic (oestradiol) and hydrophilic (5-fluorouracil) drugs*. Int. J. Pharm. 1991;74:157-168.
164. Lopes LB, Lopes JLC, Oliveira DCR, Thomazini JA, Garcia MTJ, Fantini MCA, Collett JH, Bentley M. *Liquid crystalline phases of monoolein and water for topical delivery of cyclosporin A: characterization and study of in vitro and in vivo delivery*. Eur. J. Pharm. Biopharm. 2006;63:146-155.
165. Okur NÜ, Apaydin Ş, Yavaşoğlu N, Yavaşoğlu A, Karasulu HY. *Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations*. Int. J. Pharm. 2011;416:136-144.
166. Chatterjee A, Chatterjee M, Ikushima Y, Mizukami F. *The role of solvent on selective hydrogenation of conjugated and isolated CC of Citral (3,7-dimethyl 2,6-octadienal) – a self-consistent reaction field study*. Chem. Phys. Lett. 2004;395:143-149.

167. Rauber CS, Guterres SS, Schapoval EES. *LC determination of citral in Cymbopogon citratus volatile oil*. J. Pharm. Biomed. Anal. 2005;37:597-601.
168. Silva CB, Guterres SS, Weisheimer V, Schapoval EES. *Antifungal activity of the lemongrass oil and citral against Candida spp.* Braz. J. Infect. Dis. 2008;12:63-66.
169. Bhuiyan MNI, Chowdhury JU, Begum J. *Volatile constituents of essential oils isolated from leaf and rhizome of Zingiber cassumunar Roxb.* Bangladesh J. Pharmacol. 2008;3:69-73.
170. Pithayanukul P, Tubprasert J, Wuthi-Udomlert M. *In Vitro antimicrobial activity of Zingiber cassumunar (Plai) oil and a 5% Plai oil gel.* Phytother. Res. 2007;21:164-169.